Merck & Co., Inc. (6MK.DE)
| Previous close | 118.80 |
| Open | 118.40 |
| Bid | 118.80 x 0 |
| Ask | 119.80 x 0 |
| Day's range | 118.40 - 119.40 |
| 52-week range | 91.00 - 124.40 |
| Volume | |
| Avg. volume | 1,027 |
| Market cap | 301.674B |
| Beta (5Y monthly) | 0.40 |
| PE ratio (TTM) | 913.85 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.84 (2.39%) |
| Ex-dividend date | 14 Mar 2024 |
| 1y target est | N/A |
- Insider Monkey
Here’s Why Merck & Co. (MRK) Outperformed in Q1
Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2024 investor letter. A copy of the same can be downloaded here. The fund advanced 8.92% (Institutional Shares) in the quarter compared to an 8.52% gain for the Russell 3000 Health Care Index (benchmark) and a 10.56% increase for the S&P […]
- Zacks
How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports first-quarter 2024 earnings.
- Insider Monkey
10 Best Performing Biotech ETFs in 2024
In this article, we discuss the 10 best performing biotech ETFs in 2024. If you want to skip our detailed introduction to the biotech industry and just want to take a look at some more ETFs, go directly to the 5 Best Performing Biotech ETFs in 2024. Biotechnology is a challenging field, not ideal for […]
